Syndax Pharmaceuticals (SNDX) Reports First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Syndax Pharmaceuticals (SNDX) Reports First Patient Dosed in Phase 1/2 AUGMENT-101 Trial of SNDX-5613
(NASDAQ: SNDX) Delayed: 19.32 +0.32 (1.68%)
Previous Close $19.00    52 Week High $18.03 
Open $19.21    52 Week Low $8.97 
Day High $19.59    P/E N/A 
Day Low $18.94    EPS $0.00 
Volume 1,836,656